Register Today: Leadership Academy Virtual Conference
News|Videos|November 19, 2026

Northwell Health’s Dr. Stacey Rosen sees progress in women’s health, and she wants more | HLTH 2026

Author(s)Ron Southwick

She spoke with Chief Healthcare Executive® about growing attention and investments, the need for more research, and more women in clinical trials.

Las Vegas - Dr. Stacey Rosen says she’s encouraged by the increased attention on women’s health, but she is hardly satisfied.

Rosen, the senior vice president for women’s health at Northwell Health and the executive director of the Katz Institute for Women’s Health, says the greater focus and research is long overdue.

In an interview with Chief Healthcare Executive® at the HLTH conference, Rosen says, “I do want to think that we've come a long way. But I am impatient.”

“What I'm seeing is the science is better, the realization that women's health is the reproductive organs, but far beyond that,” she says. “I'm seeing technology, innovation, pharma, investors. This is a real opportunity for all of us, frankly, to get it right and to make up for decades of less than optimal care for women.”

For generations, women weren’t included in clinical trials, she says.

“Historically, healthcare was designed by men for men, and the assumption is that women were either small men or the same, except for the reproductive organs,” she says. “And that's carried along in our guidelines, in our investment, in our policies. So being called a special population or a niche market at 51% of the population does kind of seem silly.”

A cardiologist and immediate past president of the American Heart Association, Rosen says women still aren’t getting enough representation in clinical trials.

“Heart disease is the number one killer of women, is the number one health risk,” she says. “And when we look most recently at really well done, well supported studies, we barely made 40 percent, high 40s, of the trial participants were women, and that's knowing what we know. Studies were designed for men.”

‘This should be a no-brainer’

More dollars are starting to flow into women’s health.

Last year, The Gates Foundation said that it plans to invest $2.5 billion in women’s health research over the next five years. In June, Melinda French Gates announced an investment of $215 million in women’s health, boosting her commitment to $600 million over the past two years.

WHAM, which stands for Women's Health Access Matters, released a report last year projecting that the women’s health market will reach $30 billion by 2030. Carolee Lee, founder of WHAM, told Chief Healthcare Executive® in an interview last year, “Societies are healthier if women are healthier.”

Rosen says she’s heartened by the greater investments, but she says she’s “an optimist who worries.”

“We joke at the Katz Institute, where I work, that women are the chief medical officers of their home and community,” Rosen says. “So this should be a no-brainer.”

Rosen welcomes the increased investment in menopause and the period before women enter menopause. It’s an area that has largely been ignored, which Rosen says is “kind of incredible.”

“It almost feels like the media or Hollywood has discovered menopause,” Rosen says.

Rosen says she defines women’s health as areas that are unique to women, different in women and disproportionate in women.

“Unfortunately, the things that are unique in women haven't gotten sufficient science and clinical understanding,” she says. “So you take something like menopause, correct? Every woman goes through it, hundreds of thousands a day. Yet it only happened to women. So we really didn't put the research into it. Old trials looking at hormone replacement therapy were shut down, and those questions were never addressed.”

“But the menopause transition and menopause is an incredible time in a woman's life that is hormones, but so much more: bone health and heart health and cognition, muscle challenges. That is really an important time for us to understand better, to really optimize prevention strategies for women in midlife,” Rosen says.

‘It’s a priority’

She says it’s critical to get more women participating in clinical trials. She says health systems and academic medical centers must enlist women in more studies of promising treatments.

“We need to decide that it's a priority and it's critically important,” Rosen says. “We need to know that when we do it right, we would like a percentage of women equal to the prevalence of the disease. You know, there are some things that are more common in men than women.”

She says health systems need to evaluate how large randomized clinical trials are designed.

“There's the assumption that women won't participate, so we don't ask them enthusiastically, and then it becomes almost a self-fulfilling prophecy, a cycle,” she says. “So we need to look at how we study women. There have to be real mandates with teeth, not just, ‘It would be nice to expand more female participants in trials.’ And then we have to have enough women so that we disaggregate the data. If we have enough, we could say this medication works for men, but not for women. Until we do that, we're still really not leveraging the importance of different sexes.”

Researchers need to consider ways to make it easier for women to participate, including accounting for family responsibilities and travel issues.

“It means appreciating what the hardships are for women, and quite honestly, go to the horse's mouth,” Rosen says. “Ask women why they're not participating. Is it the three times a week that you have to come in for blood tests or for other follow-ups? Is it the appreciation that it's not that important that women participate? Is it the way we're asking, or who's asking, what they look like? So you start by prioritizing it, and then you redesign the system to make it effective.”


Related to this article